Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.31 HKD | 0.00% | +7.86% | +32.29% |
May. 07 | Consun Pharmaceutical to Grant About 8.2 Million Share Options Under New Program | MT |
Mar. 29 | Consun Pharmaceutical Group Sees 15% Increase in 2023 Profit | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- The company presents an interesting fundamental situation from a short-term investment perspective.
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Its low valuation, with P/E ratio at 5.54 and 4.89 for the ongoing fiscal year and 2025 respectively, makes the stock pretty attractive with regard to earnings multiples.
- The company is one of the most undervalued, with an "enterprise value to sales" ratio at 0.74 for the 2024 fiscal year.
- The company's share price in relation to its net book value makes it look relatively cheap.
- The company is one of the best yield companies with high dividend expectations.
- For the last few months, EPS revisions have remained quite promising. Analysts now anticipate higher profitability levels than before.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- Over the past four months, analysts' average price target has been revised downwards significantly.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+32.29% | 645M | - | ||
+18.67% | 43.74B | B- | ||
+21.99% | 22.26B | B+ | ||
+16.41% | 14.9B | - | ||
+9.03% | 13.39B | B+ | ||
+40.48% | 12.12B | B | ||
-9.64% | 6.92B | B+ | ||
-0.05% | 6.79B | - | - | |
-8.87% | 5.73B | - | - | |
+12.41% | 5.47B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- 1681 Stock
- Ratings Consun Pharmaceutical Group Limited